Clinical Trial Update: A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ZL-2306 (niraparib) as maintenance therapy after first-line chemotherapy in advanced ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ZL-2306 (niraparib)

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Ovarian Cancer | Phase 3 | Status: UNKNOWN